

ERRATA

Following is a list of errata and corrections to *USP 32–NF 27*, its *Supplements*, *USP 33–NF 28 Reissue*, and its *Supplements*. The page number indicates where the item is found and in which official or pending official publication of *USP–NF*. As necessary, this list will be updated each month with the posting of monthly errata reports on www.usp.org/USPNF/newOfficialText/ and in every issue of *PF*. This information will also be available as a cumulative table in future *Supplements* and will appear in its corrected form in a future annual edition of *USP–NF*. An erratum consists of content erroneously published that does not accurately reflect the intended official or effective requirements as approved by the Council of Experts. USP staff is available to respond to questions regarding the accuracy of a particular requirement; please call 1-800-822-USPC.

USP32–NF27 Page	Title	Section	Description
1319	<i>Polysorbate 20</i>	<i>Identification</i>	Delete test C, added erroneously by erratum correction, published in <i>Pharmacopeial Forum</i> 36(4), [July–Aug. 2010]
1779	<i>Capsicum Oleoresin</i>	<i>Assay</i>	Line 7 under <i>Procedure</i> : Change “ $(CP/W)(r_U/r_S)$ in which C is the concentration,” to: $V(CP/W)(r_U/r_S)$ in which V is the volume, in mL, of the <i>Assay preparation</i> ; C is the concentration,
2973	<i>Metronidazole Tablets</i>	<i>Identification</i>	Change “ A : To a portion of powdered Tablets, equivalent to about 300 mg of metronidazole, add 20 mL of dilute hydrochloric acid (1 in 100), shake for several minutes, and filter: suitable aliquots of the filtrate respond to <i>Identification test B</i> under <i>Metronidazole</i> .” to: A : <i>Ultraviolet Absorption</i> (197U) <i>Sample solution</i> : 15 mg/mL of metronidazole from powdered Tablets in dilute hydrochloric acid (1:100). Shake for several minutes and filter.
Second Supplement to USP32–NF27			
4198	<i>Lycopene Preparation</i>	<i>Content of lycopene</i>	Lines 12–15 under <i>Test for solid preparations</i> : Change “Shake vigorously. Add 100 mL of diethyl ether, and shake vigorously. Dilute with diethyl ether to volume, shake vigorously, and allow to stand until the solid has settled.” to: Shake vigorously, and allow to stand until the solid has settled.
4220	<i>Azithromycin for Injection</i>	<i>Assay</i>	Line 12 under <i>Chromatographic system</i> : Change “Chromatograph the <i>Standard solution</i> , and record the peak responses” to: Chromatograph the <i>Standard preparation</i> , and record the peak responses
4270	<i>Ondansetron Tablets</i>	<i>Identification A</i>	Line 11 under <i>Test specimen</i> : Change “bands at 1681, 1481, 1281, and 758 cm^{-1} ” to: bands 1621, 1481, 1281, and 758 cm^{-1}

U S P 3 3 – NF28 Reissue Page	Title	CATEGORY Section	Description
R-490	<i>Ketoprofen Extended-Release Capsules</i>	PERFORMANCE TESTS Dissolution (711)	Line 13 under <i>Analysis</i> : Change “Result = $D + \Sigma R \times 100/L$ ” to: Result = $(D + \Sigma R) \times 100/L$
R-512	<i>Nateglinide</i>	ASSAY Procedure	Line 1 under <i>Mobile phase</i> : Change “Methanol and <i>Solution A</i> (1:1)” to: Methanol and <i>Buffer</i> (1:1)
R-522	<i>Oseltamivir Phosphate Capsules</i>	ASSAY Procedure	Line 2 under <i>Sample solution</i> : Change “1 mg of oseltamivir per mL” to: 1 mg of oseltamivir phosphate per mL
R-538	<i>Sertraline Hydrochloride</i>	SPECIFIC TESTS Limit of (R,R) Sertraline Hydrochloride	Line 5 under <i>Chromatographic system</i> : Change “ Column : 4.6-mm \times 25-cm; 5- μm packing L51” to: Column : 4.6-mm \times 25-cm; 5- μm packing L40

U S P 3 3 – NF28 Reissue Page	Title	CATEGORY Section	Description
First Supplement to the USP33–NF28 Reissue			
R-864	<i>Sucrose Stearate</i>	IMPURITIES Inorganic Impurities: Fats and Fixed Oils, Acid Value (401)	Line 1: Change “NMT 6.0%, determined” to: NMT 6, determined
R-878	<i>Cetirizine Hydrochloride</i>	IMPURITIES Organic Impurities: Procedure 2	Line 2 under <i>Solution A</i> : Change “and 3 g/L of monobasic sodium phosphate in water” to: and 3 g/L of monobasic sodium phosphate monohydrate in water
R-921	<i>Irinotecan Hydrochloride</i>	IMPURITIES Organic Impurities: Procedure 1: Limit of Irinotecan Hydrochloride Enantiomer	Line 4 under <i>Chromatographic system</i> : Delete “Autosampler temperature: 15°”
R-999	<i>Ziprasidone Hydrochloride</i>	IMPURITIES Organic Impurities: Procedures 2 and 3	Invert the molecular ratio in five equations from “Result = $(r_U/r_S) \times (C_S/C_U) \times (M_{r1}/M_{r2}) \times 100$ ” to: Result = $(r_U/r_S) \times (C_S/C_U) \times (M_{r2}/M_{r1}) \times 100$
Second Supplement to the USP33–NF28 Reissue			
R-1295	<i>Description and Solubility</i>	Maltose	Line 3: Change “Very soluble in ethanol” to: Very slightly soluble in ethanol
R-1396	<i>Cefdinir Capsules</i>	IMPURITIES Organic Impurities: Procedure	Last row of <i>Impurity Table 1</i> : Change “Total unspecified impurities” to: Total unidentified impurities
R-1458	<i>Ondansetron Tablets</i>	IDENTIFICATION Test A	Line 2 under <i>Acceptance criteria</i> : Change “1681, 1481, 1281, and 758 cm ⁻¹ ” to: 1621, 1481, 1281, and 758 cm ⁻¹
R-1483	<i>Valsartan and Hydrochlorothiazide Tablets</i>	PERFORMANCE TESTS Uniformity of Dosage Units (905)	Line 2 under <i>Analysis</i> : Change “Calculate the percentage of C ₂₄ H ₂₉ N ₅ O ₃ and C ₇ H ₈ ClN ₃ O ₄ S ₂ in the portion of Tablets taken: Result = $(r_U/r_S) \times (C_S/C_U) \times L$ ” to: Calculate the percentage of valsartan (C ₂₄ H ₂₉ N ₅ O ₃) and hydrochlorothiazide (C ₇ H ₈ ClN ₃ O ₄ S ₂) in the Tablet taken: Result = $(r_U/r_S) \times (C_S/C_U) \times 100$ Delete the definition for variable L.